NCT00337103_2B | R Documentation |
Kaplan-Meier digitized data from NCT00337103, figure 2B (PMID 25605862). A reported sample size of 1,102 for a primary endpoint of OS/PFS in breast cancer.
NCT00337103_2B
A data frame of 1,102 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (cap, eribulin) | |
Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33: 594–601.
summary(NCT00337103_2B)
kmplot(NCT00337103_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.